WSTAM
HAE icon

Wilbanks Smith & Thomas Asset Management’s Haemonetics HAE Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$11K – 741
2018
Q3 		$11K Buy
+100
New +$10.4K ﹤0.01% 1017

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's HAE Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 100 shares — an estimated $11K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in HAE in Q3 2018 and held it in 1 quarter. The position peaked at $11K in Q3 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 100 Haemonetics shares in Q4 2018, an estimated $11K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Haemonetics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Haemonetics position peaked at $11K in Q3 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.